

Janet T. Mills
Governor



Jeanne M. Lambrew, Ph.D.
Commissioner

Maine Department of Health and Human Services
Office of MaineCare Services - Pharmacy Unit
11 State House Station
Augusta, Maine 04333-0011
Toll Free: (866) 796-2463; TTY: Dial 711 (Maine Relay)
Fax: (207) 287-8601

To: MaineCare Providers
From: Anne-Marie Toderico, PharmD
Director of Pharmacy
Date: 9/8/2023
Re: Important Update Regarding Blood Glucose Test
Strip Dosing Limits with CGM

**** Blood Glucose Test Strip Dosing Limits with CGM ****

Dear Medicaid Provider,

Effective **10/1/2023**, a **maximum of 100 blood glucose test strips every 90 days** will be available without Prior Authorization for members currently utilizing continuous glucose monitors (CGM).

Earlier this year, we completed a retro-drug utilization review (DUR) analysis comparing member blood glucose test strip usage before and after starting CGM. Unexpectedly, member test strip utilization did not decline after starting a CGM with some members continuing to utilize 10-12 strips per day. This contrasts with 90% reduction in test strip usage reported in two clinical studies, IMPACT¹ and REPLACE². These studies demonstrated a decrease in test strip utilization, reduced hypoglycemia and no device related serious adverse events.

For questions, please contact the Change Healthcare Pharmacy Help Desk at 1-888-420-9711. Providers can also send inquiries via email to **PBA_helpdesk@changehealthcare.com**.

¹ Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R, Bolinder J. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. *Diabetologia*. 2018 Mar;61(3):539-550. doi: 10.1007/s00125-017-4527-5. Epub 2017 Dec 23. PMID: 29273897; PMCID: PMC6448969.

² Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. *Diabetes Ther*. 2017 Feb;8(1):55-73. doi: 10.1007/s13300-016-0223-6. Epub 2016 Dec 20. PMID: 28000140; PMCID: PMC5306122.